Exelixis, Inc. $EXEL Shares Sold by Three Seasons Wealth LLC

Three Seasons Wealth LLC cut its position in Exelixis, Inc. (NASDAQ:EXEL) by 48.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 30,814 shares of the biotechnology company’s stock after selling 28,705 shares during the quarter. Three Seasons Wealth LLC’s holdings in Exelixis were worth $1,677,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in Exelixis in the second quarter valued at about $1,581,991,000. AQR Capital Management LLC boosted its stake in Exelixis by 48.8% in the fourth quarter. AQR Capital Management LLC now owns 13,658,388 shares of the biotechnology company’s stock valued at $598,647,000 after acquiring an additional 4,477,029 shares during the period. Norges Bank acquired a new stake in shares of Exelixis during the 4th quarter worth approximately $106,460,000. Caisse de depot et placement du Quebec bought a new stake in shares of Exelixis in the 2nd quarter worth approximately $113,951,000. Finally, Bank of New York Mellon Corp acquired a new position in Exelixis during the 2nd quarter valued at approximately $107,803,000. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Insider Buying and Selling at Exelixis

In related news, Director Mary Beckerle sold 9,812 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $53.66, for a total transaction of $526,511.92. Following the completion of the sale, the director owned 16,079 shares in the company, valued at $862,799.14. This represents a 37.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 2.60% of the company’s stock.

Wall Street Analyst Weigh In

EXEL has been the topic of several analyst reports. Truist Financial dropped their target price on Exelixis from $56.00 to $52.00 and set a “hold” rating on the stock in a research report on Thursday, August 6th. Morgan Stanley lifted their price target on Exelixis from $50.00 to $53.00 and gave the company an “equal weight” rating in a research report on Thursday, July 23rd. Stifel Nicolaus increased their target price on shares of Exelixis from $47.00 to $51.00 and gave the company a “hold” rating in a research note on Thursday, August 6th. Citizens Jmp lifted their price target on Exelixis from $50.00 to $55.00 and gave the stock a “market outperform” rating in a research note on Wednesday, June 24th. Finally, Royal Bank Of Canada increased their target price on Exelixis from $43.00 to $46.00 and gave the company a “sector perform” rating in a report on Tuesday, July 7th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Exelixis presently has an average rating of “Hold” and a consensus target price of $50.07.

Exelixis News Summary

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Zacks Research upgraded Exelixis from “Strong Sell” to “Hold,” improving the tone around the stock. Exelixis is a Top-Ranked Value Stock
• Positive Sentiment: Zacks Research modestly raised its EPS forecasts for Exelixis’ fourth quarter of 2027, second quarter of 2028 and full-year 2028. The FY2028 estimate increased to $4.21 from $4.18, suggesting slightly better long-term earnings expectations.
• Positive Sentiment: Exelixis has broken out to new highs following its earnings report, reflecting continued investor demand and favorable chart momentum. Exelixis Reaches New 52-Week High Following Analyst Upgrade
• Positive Sentiment: The company is being highlighted as a highly ranked value stock, which may attract investors seeking relatively attractive valuation and earnings potential.
• Neutral Sentiment: Investors are watching a potential FDA action tied to the cancer-treatment business. A favorable decision could provide another catalyst, while the timing and outcome remain uncertain. Cancer Stock Breaks Out to Highs
• Negative Sentiment: Despite beating quarterly EPS expectations, Exelixis’ latest revenue came in below consensus estimates. The earnings “snag” means investors may need evidence that growth can accelerate before the breakout is sustained. IBD Stock of the Day Exelixis Hits Earnings Snag and Then Breaks Out

Exelixis Stock Down 0.2%

Shares of EXEL opened at $59.01 on Friday. Exelixis, Inc. has a 12 month low of $33.76 and a 12 month high of $59.72. The company’s fifty day moving average is $55.07 and its 200-day moving average is $49.50. The firm has a market cap of $14.62 billion, a price-to-earnings ratio of 18.56, a price-to-earnings-growth ratio of 1.76 and a beta of 0.42.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $0.06. Exelixis had a return on equity of 42.17% and a net margin of 35.33%.The business had revenue of $628.69 million for the quarter, compared to analyst estimates of $636.40 million. During the same quarter in the prior year, the firm posted $0.75 EPS. The firm’s revenue for the quarter was up 10.6% on a year-over-year basis. As a group, research analysts predict that Exelixis, Inc. will post 3.19 earnings per share for the current fiscal year.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.